Targeting of Th1-associated chemokine receptors CXCR3 and CCR5 as therapeutic strategy for inflammatory diseases.
CXCR3 and CCR5 are chemokine receptor that are predominantly expressed on the surface of Th1 polarized T cells. In a variety of human and experimental autoimmune diseases the enhanced expression of CXCR3 and CCR5 binding chemokine ligands is followed by the recruitment of CXCR3- and CCR5-positive T cells, indicating an important role for these chemokine receptors in T cell-mediated tissue damage. In this review, we summarize a number of in vivo studies available on the neutralization of CXCR3 and CCR5 in inflammatory disease, and specifically focus on the potential therapeutic effects of CXCR3 and CCR5 blockade in human autoimmune disease and organ transplantation.
III. Medizinische Klinik, Universtätsklinikum Hamburg Eppendorf, Martinistrasse 52, 20251 Hamburg D, Germany.
J E
JE
Turner
O M
OM
Steinmetz
R A
RA
Stahl
U
U
Panzer
D000818:Animals; D001327:Autoimmune Diseases / Q000276:immunology / Q000628:therapy*; D016503:Drug Delivery Systems; D006801:Humans; D008024:Ligands; D019713:Receptors, CCR5 / Q000187:drug effects / Q000378:metabolism*; D054367:Receptors, CXCR3 / Q000187:drug effects / Q000378:metabolism*; D018417:Th1 Cells / Q000276:immunology*
D008024:Ligands; D019713:Receptors, CCR5; D054367:Receptors, CXCR3